Please assess the completion status of the following clinical trial:

Trial Title: 18F Fluciclovine (FACBC) PET/CT in Patients With Rising PSA After Initial Prostate Cancer Treatment

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* History of histologically confirmed adenocarcinoma of the prostate post curative-intent local treatment (radical prostatectomy, local radiotherapy, brachytherapy).~* Suspicion of recurrent prostate carcinoma after previous presumed definitive therapy for organ confined disease defined as :~* Post prostatectomy: Detectable or rising PSA level that is \>0.2 ng/mL with a second confirmatory level of \>0.2 ng/mL~* Post non-prostatectomy: PSA rise ≥ 2ng/mL over nadir~* Negative or equivocal findings on standard-of-care imaging for restaging of disease in the previous 60 days consisting of: Whole-body 99mTc bone scintigraphy or NaF PET-CT; and either CT or MRI of the pelvis (or the abdomen and pelvis).~* Being considered for salvage therapy~* Any non-surgical local treatment such as previous cryotherapy, external beam radiation, or HiFU (Ultrasound) must have occurred at least 1 year in the past.~* Previous brachytherapy treatment will have occurred at least 2 years in the past~* Ability to understand and the willingness to sign a written informed consent.~Exclusion Criteria:~* Ongoing treatment with any systemic therapy intended for the treatment of prostate cancer (e.g., antiandrogen or LHRH agonist or antagonist)~* Androgen deprivation therapy (ADT) in the past 3 months~* History of bilateral orchidectomy~* Inability to tolerate 18F-fluciclovine PET/CT

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 18F-fluciclovine PET CT (Type: EXPERIMENTAL): Single intravenous administration of 18F-fluciclovine PET CT.

Based on this trial design, predict the completion outcome and termination type (if applicable).